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1. Introduction
Alzheimer’s disease (AD) is an incurable and progressive neurodegenerative disorder and the
most common form of dementia that occurs with aging. The main hallmarks of this disease are
the extracellular deposition of amyloid plaques and the intracellular aggregation of tangles in
the brain [1, 2]. Although the causes of both the onset and progression of AD are still uncertain,
much evidence, including results of genetic analysis, indicates that amyloid precursor protein
(APP) itself and its proteolytic processing are responsible for AD. Indeed, familial forms of AD
(FAD) have mutations [3] or a duplication of the APP gene [4] or mutations in the presenilin1 or
2 (PS1 or PS2) genes [5-7] that code for a catalytic component of the γ-secretase complex [8].
Although APP plays a central role in AD [1, 2], the physiological function of this membrane
protein is not clear [9]. On the other hand, γ-secretase was first identified as a protease that
cleaves APP within the transmembrane domain and produces amyloid-β (Aβ) peptides [10],
which are the main constituent of amyloid plaques and are thought to be involved in AD
pathogenesis. However, similar to the physiological functions of APP, those of γ-secretase
are also still unclear [11, 12].
The signaling hypothesis suggests that the primary function of γ-secretase is to regulate signal‐
ing of type 1 membrane proteins (the amino terminus is extracellular, and the carboxy terminus
is cytoplasmic); this was proposed by analogy of Notch signaling [13-15]. Notch is a family of
evolutionarily conserved type 1 membrane proteins that mediate the fates of numerous cells in
both invertebrates and vertebrates [16-18]. The molecular mechanism of the Notch signaling
pathway is unique because it is controlled by proteolytic cleavage reactions [19, 20]. In the can‐
onical Notch signaling pathway, ligands bind to the extracellular domain of Notch expressed
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on neighboring cells and trigger sequential proteolytic cleavage. Finally, the intracellular do‐
main (ICD) of Notch (NICD) is released from the cell membrane by γ-secretase; NICD then
translocates into the nucleus where it modulates gene expression through binding to transcrip‐
tion factors. Therefore, γ-secretase plays a central regulatory role in Notch signaling.
Recently, more than five dozen type 1 transmembrane proteins, including Notch and APP,
have been reported as substrates for γ-secretase [21]. The ICDs of these proteins are also re‐
leased from the cell membrane [13-15, 22]. Furthermore, it has been shown that some of
these ICDs exist in the nucleus. These processes are very similar to those involved in Notch
signaling. Thus, the common enzyme γ-secretase modulates the proteolysis and turnover of
putative signaling molecules; this suggests that mechanisms similar to the Notch signaling
pathway may widely contribute to γ-secretase–regulated signaling [13-15, 23]. Indeed, it has
been shown that the ICD of APP (AICD), which is released from the cell membrane by γ-
secretase, also translocates to the nucleus [24-26] and may function as a transcriptional regu‐
lator [27, 28]. These observations suggest the existence of APP signaling.
To test the hypothesis that APP has a signaling mechanism similar to that of Notch, we es‐
tablished embryonic carcinoma P19 cell lines that overexpressed AICD [29], which may
mimic signaling mechanisms. Although neurons differentiated from these cell lines, AICD
expression induced dynamic changes in gene expression profile and neuron-specific apopto‐
sis [30]. These results suggest that APP also has a signaling mechanism, which may be close‐
ly related to AD.
In this chapter, we first summarize current research progress regarding Notch, APP, and γ-
secretase. We also focus on the signaling hypothesis; γ-secretase–regulated mechanisms
similar to Notch signaling may widely play roles in signaling events involving type 1 trans‐
membrane proteins, including APP. Next, we review recent evidence supporting the exis‐
tence of APP signaling. Furthermore, we discuss the possibility that APP signaling is
involved in the onset and progression of AD.
2. γ-Secretase controls Notch signaling
Notch is a family of evolutionarily conserved type 1 membrane proteins with a mass of
about 300 kDa [31] that mediates fates of numerous cells in both invertebrates and verte‐
brates [16, 17]. For example, cells expressing the major ligand Delta inhibit the neural differ‐
entiation of neighboring Notch-expressing cells during neurogenesis. Disruption of or
disorder in Notch signaling leads to developmental defects or cancer in mammals [18].
While Drosophila has only one Notch gene, four Notch isoforms (Notch1 to 4) have been
identified in mammals. The typical Notch protein contains 36 tandem epidermal growth fac‐
tor (EGF)-like repeats in its extracellular domain, and six tandem ankyrin-like (CDC10) re‐
peats, a nuclear localization signal, and a PEST sequence in its intracellular domain [31]. The
11th and 12th EGF-like repeats are essential for binding to its ligands [32]. Notch is cleaved
in the trans-Golgi network, apparently by furin-like covertase, and is expressed on the cell
surface as a heterodimer [33].
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Figure 1. Notch signaling pathway. Notch proteins are expressed on the cell surface as heterodimers after cleavage at
the S1 site by furin. The binding of Notch to the ligand triggers sequential proteolytic cleavage of the regulated intra‐
membrane proteolysis (RIP). When Notch binds to the ligand, Notch is cleaved at the S2 site in the juxtamembrane
region by TACE or ADAM protease. Next, the remaining protein stub is further cleaved by γ-secretase at the S3 and S4
sites within the transmembrane domain and NICD is released from the membrane. Then, NICD translocates into the
nucleus and binds to the CSL together with MAML. The resultant CSL–NICD–MAML complex removes co-repressors
(Co-R) from CSL transcription factor and recruits a co-activator (Co-A), resulting in conversion from repressor to activa‐
tor. Finally, the complexes of CSL-NICD-MAML-Co-activators promote transcription of the target genes.
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Drosophila has two different Notch ligands, Delta [34] and Serrate [35]. In mammals, two
families of Notch ligands, Delta-like protein family (Dll1, 3, and 4) [36-38] and Jagged family
(Jagged 1 and 2) [39, 40], have been identified. The extracellular domains of all these ligands
also contain variable number of EGF-like repeats, e.g., Drosophila Delta has nine, while most
vertebrate Deltas have eight, and Caenorhabditis elegans Lag-2 has two repeats. All these li‐
gands share a single copy of a 2nd cysteine-rich conservative motif called the DSL (Delta:
Serrate: Lag-2) domain [41], which is essential for binding to Notch [42].
As shown in Fig.1, in the canonical Notch signaling pathway, ligands bind to the extracellu‐
lar domain of Notch proteins on neighboring cells and trigger sequential proteolytic cleav‐
age reactions; this is called the regulated intramembrane proteolysis (RIP) mechanism [43].
Precise steps of Notch processing are mentioned in section 4.2 of this chapter. In brief, first,
Notch is cleaved within the juxtamembrane (JM) domain by metalloproteases to remove
most of the extracellular region [44, 45]. Next, the remaining protein stub is further cleaved
by γ-secretase within the transmembrane (TM) domain and NICD is released from the
membrane [46-48]. The released NICD translocates to the nucleus and controls the expres‐
sion of certain genes through binding to transcription factors. Thus, γ-secretase plays a cen‐
tral regulatory role in Notch signaling.
Members of the CSL transcription factor family (CBF1/RBP-jκ in mammals, Su(H) in Droso‐
phila, and Lag-1 in C. elegans) are major downstream targets of Notch signaling [19]. NICD
binds to CSL transcription factors, and six tandem ankyrin-like repeats in NICD are essen‐
tial for binding to CSL transcription factors [49]. NICD also binds to Mastermind-like pro‐
teins (MAML family in mammals) [50], thus forming the CSL-NICD-MAML complex. The
formation of these complexes results in removal of co-repressors from CSL and recruitment
of co-activators, such as P/CAF and P300 [50, 51]. Through this process, the CSL complex is
converted from a transcriptional repressor to an activator. Finally, these complexes bind to
the cis-acting DNA sequences of target genes, such as Hes (Hairy/Enhancer of split in Droso‐
phila), which encode the basic helix-loop-helix (bHLH) transcription factors, and promote
their transcription [52].
3. Amyloid Precursor Protein (APP)
3.1. Overview of APP
APP was identified as a cDNA cloned using a partial amino acid sequence of the Aβ frag‐
ment isolated from the amyloid plaque of AD brains [53]. This cDNA coded for an evolutio‐
narily conserved type 1 transmembrane protein. Fig. 2 shows schematic diagram of APP
protein. Although APP is expressed in many tissues, this protein especially accumulates in
the synapses of neurons. The human APP gene is about 240 kb in length containing at least
18 exons [54] and is localized on the long arm of chromosome 21 [53], an extra copy of which
is present in patients with Down’s syndrome (trisomy 21). Several alternative splicing iso‐
forms of APP have been found, which differ mainly in the absence (APP-695, predominantly
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expressed in neurons) or presence (APP-751 and APP-770) of the Kunitz protease inhibitor
(KPI) domain toward the N-terminus of the protein [55].
As described below, APP undergoes sequential proteolytic cleavage reactions to generate
the extracellular fragment, intracellular fragment (AICD), and Aβ fragment that is located in
the membrane-spanning region. Note that both the extracellular fragment and AICD are
generated at the same time as Aβ. Extensive post-translational modifications of APP, such as
glycosylation, phosphorylation, and tyrosine sulfation, have been observed.
Mammals have two other members of APP family called APP-like protein 1 (APLP1) and 2
(APLP2) [56]. APLP1 expression is restricted to neurons. On the other hand, expression of
APLP2 is detected in many tissues, although it is highly enriched in the brain. These APP
family proteins share conserved domains, such as the E1 and E2, in the extracellular region.
The E1 domain contains several subdomains, such as a growth factor-like domain and a
metal-binding motif [57]. The E2 domain has a coiled coil dimerization motif and may bind
proteoglycans in the extracellular matrix [58].
Interestingly, the amino acid sequence of the Aβ fragment is not highly conserved and is
unique to APP; on the other hand, the highest degree of sequence conservation is found in
the ICD not only within the APP homologues [29] but also within the APP family [9]. This
strong sequence conservation most likely reflects functional importance of the ICDs in the
APP family proteins.
Figure 2. Schematic domain structure of APP. APP protein family shares the conserved E1 and E2 domains in their
extracellular region. The E1 domain contains N-terminal growth factor-like domain (GFLD) and copper-binding do‐
main (CuBD). The E1 domain is linked via acidic domain to the carbohydrate domain including E2 domain, which con‐
sists of RERMS sequence and central APP domain (CAPPD). E2 domain is followed by the Aβ region, and the
intracellular domain (AICD) which is the most conserved region. Although the Kunitz protease inhibitor (KPI) domain
is present at the indicated site in APP-751 and APP-770, APP-695 lacks this domain.
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3.2. Proposed APP functions
Although the physiological functions of APP are not clear, several possibilities have been
proposed. The most considerable functions are synapse formation and repair [59, 60]. In‐
deed, APP expression is  upregulated after neural  injury as well  as during neuronal dif‐
ferentiation [59, 60].  After translation in the soma, APP is transported in an anterograde
manner to the synaptic region, where the amount of APP is correlated with synaptogene‐
sis.  APP  knockout  mice  show  impaired  long-term  potentiation  and  declined  memory
without remarkable neuronal loss [61]. This evidence also supports this idea.
It has also been suggested that APP acts as a cell adhesion molecule and plays a role in cell–
cell interaction. Indeed, the E1 and E2 domains can interact with extracellular matrix pro‐
teins and heparan sulfate proteoglycans [57, 58]. In addition, it has also been shown that ex‐
tracellular domains of APP family proteins can interact with each other in trans. Therefore,
APP family proteins may bind to each other in a homophilic or heterophilic manner to en‐
hance cell–cell adhesion [62].
As APP may have a signaling mechanism, as described in detail below, the idea that APP is
a cell-surface receptor is interesting. Indeed, several candidates of ligand for APP have been
proposed. For example, F-spondin [63] and Nogo-66 [64] receptor bind to the extracellular
domain of APP and regulate the production of Aβ. In addition, Aβ itself can also bind to the
extracellular domain of APP [65].
3.3. Aβ amyloid
Aβ is the main constituent of an amyloid plaque, which is thought to be the hallmark and a
major cause of AD pathogenesis in the brain. Thus, the amyloid hypothesis is generally ac‐
cepted as the mechanism of the onset and progression of AD. The traditional amyloid hy‐
pothesis is that overproduced Aβ forms insoluble amyloid plaques, which are commonly
observed in the AD brain and are believed to be the toxic form of APP and responsible for
neurodegeneration [66].
As detailed in section 4.2., Aβ is generated after sequential cleavage of APP by β- and γ-sec‐
retases. Although these fragments range from 36 to 43 amino acid residues in length, Aβ40
and Aβ42 are the most common isoforms. Aβ40 is predominant over Aβ42, but Aβ42 is
more amyloidogenic [67] and is, therefore, thought to be closely associated with AD. Fur‐
thermore, similar amyloid plaques are found in particular variants of Lewy body dementia
[68] and in the muscle disease inclusion body myositis [69]. Aβ also forms aggregates that
coat cerebral blood vessels in cerebral amyloid angiopathy (CAA), which is observed in over
90% of AD patients [70].
Deposition of  Aβ in  the  AD brain  is  thought  to  be  formed due to  imbalances  between
the production of  Aβ and its  removal  from the brain through various clearance mecha‐
nisms,  including enzyme-mediated degradation [71].  Therefore,  mechanisms of  not  only
production but also degradation of Aβ have been studied extensively. As a result, sever‐
al  candidates  for  Aβ degradation enzymes are  proposed.  Neprilysin (NEP) and insulin-
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degrading enzyme (IDE) are expressed in neurons as well as within the vasculature and
the levels of both these enzymes are reduced in AD [71];  therefore, these enzymes have
been  well  studied  in  relation  to  AD.  Interestingly,  it  has  been  reported  that  APOE  e4,
which is the most-established genetic risk factor for the onset of AD and CAA, is associ‐
ated with reduced levels of both enzymes [72, 73]. Furthermore, other candidates for Aβ
degradation  enzymes  have  been  proposed,  including  endothelin-converting  enzymes  1
and 2 (ECE-1 and ECE-2) [74] and angiotensin-converting enzyme (ACE) [75]. The levels
of plasmin and plasminogen activators (uPA and tPA) and ECE-2 have also been shown
to be reduced in the AD brain [71].
4. γ-Secretase
4.1. Overview of γ-secretase
γ-Secretase  was  first  identified  as  a  protease  that  cleaves  APP  within  the  TM  domain
and produces Aβ peptides [10],  which is thought to be a major cause of the pathogene‐
sis in the AD brain.
γ-Secretase is a complicated complex composed of PS, nicastrin (NCT), anterior pharynx
defective-1 (Aph-1), and PS enhancer-2 protein (Pen-2) [8, 11, 12]. Two PS genes, PS1  lo‐
cated on chromosome 14 [5] and PS2  located on chromosome 1 [6, 7],  have been identi‐
fied by genetic  linkage analyses  as  the  genes  responsible  for  early-onset  FAD.  The PS1
and PS2  genes  encode proteins  with  eight  or  nine  transmembrane  domains  of  467  and
448  amino  acids,  respectively,  with  about  65% sequence  identity  between  the  two  pro‐
teins.  Both  proteins  are  the  catalytic  components  of  the  γ-secretase  complex.  Although
both PS1 and PS2 are expressed ubiquitously in the brain and peripheral tissues of adult
mammals, PS1 expression level is significantly higher than that of PS2 [76]. NCT is a sin‐
gle-pass membrane protein and may recognize the substrate proteins of γ-secretase [77].
Indeed, the extracellular domain of NCT resembles an aminopeptidase, but lacks catalyt‐
ic  residues.  Thus,  this  domain can interact  with the free N-terminal  of  stubs of  γ-secre‐
tase  substrates  generated  by  ectodomain  shedding  [78];  hence,  shedding  of  γ-secretase
substrates  may  be  essential  for  the  production  of  free  N-termini  of  these  proteins  re‐
tained in the membrane to  be recognized by NCT.  Aph-1 may act  as  a  scaffold during
the process of γ-secretase complex assembly, and Pen-2 may act as a trigger for the pro‐
teolytic cleavage of PS in order to activate it [11, 12].
The physiological functions of γ-secretase have not been clarified. However, this protease
can cleave a surprisingly large number of transmembrane proteins [79]. Indeed, more than
five dozen proteins, most of which are type 1 membrane proteins, have been reported as γ-
secretase substrates [21]. Interestingly, these substrates have a wide range of biological func‐
tions. Representative γ-secretase substrates are shown in Table 1.
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Substrate Function PS or ICD function
ApoER2 Lipoprotein receptor, neuronal
migration
Activates nuclear reporter
APP Precursor to Aβ, adhesion, trophic
properties, axonal transport?
Ab generation, release of ICD,
Complex with Fe65/Tip60, Cell death?
APLP1/2 Cell adhesion? Forms complex with Fe65 and Tip60
β-Catenin Transduce Wnt signals stabilize
adherens junctions
Facilitates phosphorylation
CD43 Signal transduction Signaling molecule?
CD44 Cell adhesion Activates TRE-mediated nuclear transcription
CSF1-R Protein tyrosine kinase Unknown
CXCL16 & CX3CL1 Membrane chemokine ligands Unknown
DCC Axon guidance, tumor suppressor Activates nuclear reporter
Delta Notch ligand Transcriptional regulation
E-cadherin Cell adhesion Promotes disassembly of adhesion complex
ERBB4 Receptor tyrosine kinase Regulates heregulin-induced growth inhibition
HLA-A2 MHC class I molecule Unknown
IFN-αR2 Subunit of type I IFN-α receptor Transcriptional regulation
Insulin receptor Receptor tyrosine kinase Accumulates in nucleus
IGIF-R Receptor tyrosine kinase Unknown
IL-1RI Cytokine receptor Unknown
IL-1RII Cytokine receptor Unknown
Jagged Notch ligand Modulates AP-1-mediated transcription
LAR Receptor tyrosine phosphatase Accumulates in nucleus
LDLR Lipoprotein receptor Unknown
LRP Scavenger and signaling receptor Activates nuclear reporter
Na channel β-subunit Cell adhesion, an auxiliary subunit
of voltage-gated Na channel
Alters cell adhesion and migration
N-cadherin Cell adhesion Promotes CBP degradation
Nectin-1α Adherens junction, synapse
receptor
Remodeling of cell junctions?
Notch1-4 Signaling receptor Transcriptional regulation
NRADD Apoptosis in neuronal cells Modulates glycosylation/maturation of NRADD
P75NTR Neurotrophin co-receptor,
dependence receptor
Modulates p75-TrkA complex? Nuclear signaling?
γ-Protocadherin Cell adhesion, neuronal
differentiation
Regulation of gene transcription?
Syndecan-3 Cell surface proteoglycan co-
receptor
Regulation of membrane-targeting of CASK
Telencephalin Cell adhesion Turnover of telencephalin
Tyrosinase,Tyrosinase-
related protein 1/2
Pigment synthesis Intracellular transport of Post-Golgi Tyr-containing
vesicles
Vasorin TGF-β inhibitor Unknown
Table 1. Substrates for γ-secretase
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4.2. Some γ-secretase substrates share a common proteolytic process
Fig.3 shows the proteolytic processes of Notch, APP, and CD44. There are surprising simi‐
larities between these processes and all of these processes follow the RIP mechanism. For ex‐
ample, in the canonical Notch signaling pathway, ligands bind to the extracellular domain
of Notch on neighboring cells and trigger sequential proteolytic cleavage reactions (the RIP
mechanism) and shedding at the S2 site by TACE or ADAM protease making the truncated
Notch [44, 45]. Truncated Notch is further cleaved by γ-secretase in at least two sites within
the TM domain [46-48], i.e., at the S3 site to release NICD and at the S4 site to release the
remaining small peptide (Nβ). As mentioned above, NICD, which is released from the cell
membrane to the cytoplasm by γ-secretase, translocates to the nucleus where its activity is
expressed through binding to transcription factors.
The proteolytic process of APP is very similar to that of Notch and also follows the RIP
mechanism. Cleavage of APP by α- secretase [80] or β-secretase [81] at the α- or β-site, re‐
spectively, within the JM region results in shedding of almost the entire extracellular do‐
main and generates membrane-tethered α- or β-carboxy terminal fragments (CTFs). Several
zinc metalloproteinases, such as TACE and ADAM [82, 83], and the aspartyl protease
BACE2 [84] can cleave APP at the α-site, while BACE1 (β-site APP cleaving enzyme) cleaves
APP at the β-site [81]. Once the extracellular domain has been shed, the remaining stub is
further cleaved at least twice by γ-secretase within the TM domain at γ- and ε-sites resulting
in production of either non-amyloidogenic p3 peptide (in combination with α-secretase) or
amyloidogenic Aβ (in combination with BACE1), respectively, and AICD [11, 12]. As dis‐
cussed in the next paragraph, although a large proportion of AICD is rapidly degraded in
the cytoplasm, a small amount of the remaining AICD may translocate to the nucleus.
It has been reported that several other type 1 membrane proteins also follow the RIP mecha‐
nism and their ICDs are released from the cell membrane [13, 14, 22]. For example, as shown
in Fig.3, the process of sequential proteolytic cleavage of CD44, which is important for im‐
mune system function, is very similar to those of Notch and APP [22]. In addition, the ICD
of this protein (CD44ICD) also translocates to the nucleus (Fig.3).
As discussed here, several γ-secretase substrates follow the RIP mechanism. The ICDs of
these substrates are released from the cell membrane by γ-secretase, and these ICDs translo‐
cate to the nucleus. These processes are very similar to those involved in Notch signaling.
Therefore, the observations that the common enzyme, γ-secretase, modulates proteolysis
and the turnover of possible signaling molecules led to the attractive idea, the signaling hy‐
pothesis, which suggests that mechanisms similar to those occurring in the Notch signaling
pathway may contribute widely to γ-secretase–regulated signaling mechanisms.
Actually, Dll1, a major ligand of Notch, is cleaved sequentially by metalloproteases and γ-
secretase, and ICD of Dll1 (Dll1IC) is released from the cell membrane and then translocates
to the nucleus [85, 86]. Furthermore, we have shown that Dll1IC then binds to Smad 2 and 3,
which are transcription factors involved in the TGF-β/activin signaling pathway, and may
alter transcription of specific genes that are involved in neuronal differentiation [87]. These
results suggest that Dll1 also has a signaling mechanism similar to that of Notch.
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Figure 3. Similarities in the proteolytic processes among Notch, APP, and CD44. (A) In response to ligand binding, Notch
undergoes shedding due to metalloprotease cleavage at the S2 site within the juxtamembrane domain. After shedding
the extracellular domain, the remaining Notch stub is further cleaved by γ-secretase at S3 and S4 sites within the trans‐
membrane domain. This sequential proteolysis produces NICD and Nβ fragment. (B) Cleavage of APP by α-secretase or β-
secretase at the α-site or β-site, respectively, within the juxtamembrane domain results in shedding of almost the entire
extracellular domain and generates membrane-tethered α- or β-carboxy terminal fragments (CTFs). Several zinc metallo‐
proteinases and BACE2 can cleave APP at the α-site, while BACE1 cleaves APP at the β-site. After shedding the extracellular
domain, the remaining stub is further cleaved at least twice within the transmembrane domain at γ- and ε-sites by γ-secre‐
tase, producing either p3 peptide (in combination with α-secretase) or Aβ (in combination with BACE1), respectively, and
AICD. (C) Several stimuli, such as PKC activation and Ca2+ influx, trigger ectodomain cleavage of CD44 by a metalloprotease
at the site within the juxtamembrane domain, resulting in the secretion of soluble CD44 (sCD44). After shedding the ex‐
tracellular domain, the remaining CD44 stub is further cleaved by γ-secretase at two sites within the transmembrane do‐
main. This sequential proteolysis produces the CD44ICD and CD44β, an Aβ-like peptide.
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4.3. Is γ-secretase a proteasome of the membrane?
As  mentioned  above,  more  than  five  dozen  γ-secretase  substrates,  most  of  which  are
type  1  membrane  proteins,  have  been reported.  This  raises  the  simple  question  against
the  signaling  hypothesis,  why  so  many  membrane  proteins  can  transmit  signals  to  the
nucleus.  In  reply  to  this  question,  another  possibility  that  γ-secretase  acts  as  a  protea‐
some  of  the  membrane  has  been  proposed  [11,  12].  Indeed,  as  the  ICDs  of  these  sub‐
strates  including  AICD,  which  are  released  by  γ-secretase,  are  rapidly  degraded  [24,
88],  it  is  usually difficult  to detect  their  ICDs by western blotting.  Furthermore,  ectodo‐
main  shedding  seems  to  be  constitutive  for  some  substrates,  and  ligand  binding  has
been reported to  enhance  only  cleavage of  Notch [47],  Delta  [87],  Syndecan-3  [89],  and
ERBB4  [90].  In  addition,  much  evidence  supporting  the  signaling  hypothesis  was  ob‐
tained  in  overexpression  assays  that  differ  somewhat  from normal  physiological  condi‐
tions.  Based  on  these  observations,  the  proteasome  hypothesis  suggesting  that  the
primary  function  of  γ-secretase  is  to  facilitate  the  selective  disposal  of  type  1  mem‐
brane proteins has been proposed [11,  12].
Although the proteasome hypothesis for γ-secretase is reasonable and potent, there is no
doubt that the certain signaling mechanisms regulated by γ-secretase, such as Notch sig‐
naling, exist. Therefore, it is likely that different functions of γ-secretases reflect their var‐
iant  complexes  in  different  combinations  with  multiple  components,  such  as  Aph-1,
Pen2,  and/or PS isoforms,  with different cellular functions,  such as roles in signaling or
degradation.
In  addition,  it  seems  that  a  small  proportion  of  ICDs  of  these  substrates  that  are  re‐
leased  by  γ-secretase  are  sufficient  for  signaling  mechanisms.  Generally,  γ-secretase
substrates  like  APP  are  considerably  more  abundant  than  transcription  factors,  which
are  usually  rare  molecules.  Although  a  large  proportion  of  ICDs  of  these  substrates
are  rapidly  degraded,  a  small  amount  of  the  remaining  ICDs  may  be  sufficient  for
their  signaling functions with small  quantities  of  transcription factors.  Thus,  the majori‐
ty  of  ICDs  of  these  substrates  may  be  degraded,  and  only  a  small  proportion  may
play roles  in signaling.
In relation to this issue, an attractive idea has been proposed in which a certain stimulus
controls  APP signaling through phosphorylation and dephosphorylation of  AICD. Since
AICD is stabilized [91] and translocated into the nucleus by Fe65 [26],  it  is thought that
Fe65 is essential for the signaling function of AICD. Non-phosphorylated AICD can bind
to  Fe65  and  form a  complex;  thus,  this  complex  is  stabilized  and  immediately  translo‐
cates to the nucleus, where it mediates the expression of target genes in association with
Tip60.  On the  other  hand,  phosphorylated AICD cannot  bind to  Fe65.  Therefore,  phos‐
phorylated AICD without Fe65 cannot translocate to the nucleus.  Phosphorylated AICD
that remains in the cytosol is rapidly degraded by degradation enzymes such as the pro‐
teasome and/or  IDE.  Indeed,  it  has  been  reported  that  phosphorylation  at  Thr668  in  the
APP-695 isoform strongly inhibited binding to Fe65 [92, 93].
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5. The role of AICD
5.1. Signaling functions of AICD
As mentioned above, the observations that the common enzyme, γ-secretase, modulates
proteolysis and the turnover of possible signaling molecules led to the signaling hypothesis.
This suggests that mechanisms similar to the Notch signaling pathway may contribute
widely to γ-secretase–regulated signaling mechanisms, including APP signaling. If APP sig‐
naling exists, it may be closely related to AD.
Actually, there is accumulating evidence for the existence of APP signaling and its contribu‐
tion to the onset and progression of AD. As mentioned above, the highest degree of se‐
quence conservation within the APP homologues is found in the ICD [9, 29]. This sequence
conservation suggests the functional importance of AICD, which may reflect the existence of
APP signaling. In addition, several AICD-interacting proteins, which may regulate AICD
stability, cellular localization, and transcriptional activity, have been identified. Based on
this, several models of APP signaling have also been proposed. As mentioned above, it has
been suggested that AICD recruits Fe65 proteins and translocates into the nucleus where the
AICD-Fe65-Tip60 ternary complex may control transcription of target genes [27]. Further‐
more, NEP gene expression requires binding of the AICD to its promoter [94].
Transgenic mice overexpressing both AICD and Fe65 showed abnormal activity of glycogen
synthase kinase 3 beta (Gsk3b protein) [95], leading to hyperphosphorylation and aggrega‐
tion of tau. This results in microtubule destabilization and the reduction of nuclear β-catenin
levels causing a loss of cell-cell contact that may contribute to neurotoxicity in AD. Subse‐
quent neurodegeneration and working memory deficits were also observed in these trans‐
genic mice [96]. In other experiments, similar transgenic mice exhibited abnormal spiking
events in their electroencephalograms and susceptibility to kainic acid-induced seizures in‐
dependent of Aβ [97]. Furthermore, the function of c-Abl kinase in the transcriptional regu‐
lation of AICD was reported and c-Abl was shown to modulate AICD-dependent cellular
responses, transcriptional induction, as well as apoptotic responses [98]. Interestingly, ele‐
vated AICD levels have also been reported in AD brains [96]. In addition, AICD was detect‐
ed in the nucleus in injured brains [99]. Taken together, it is likely that APP signaling
changes the expression of certain genes, which may cause AD pathology.
To explore APP signaling, we established several AICD-overexpressing embryonic carcinoma
P19 cell lines [29]. Undifferentiated AICD-overexpressing cells retained epithelial cell-like mor‐
phology and healthy as well as control cells. Although neurons were differentiated from these
cell lines after aggregation culture with all-trans-retinoic acid (RA) treatment, AICD expression
induced neuron-specific cell death. Indeed, as shown in Fig.4, while neurons from control cells
that carried the vector alone were healthy, almost all neurons differentiated from AICD-overex‐
pressing P19 cells showed severe degeneration, becoming spherical with numerous vacuoles
and detaching from the culture dishes 4 days after the induction of differentiation.
Since DNA fragmentation was detected, these cells died by apoptosis. In addition, all termi‐
nal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP)-biotin
nick end-labeling (TUNEL)-positive cells were also Tuj1-positive neurons. Taken together,
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we concluded that AICD could induce neuron-specific apoptosis [29]. The effects of AICD
were restricted to neurons, with no effects observed in non-neural cells.
Thus, although further studies are required, these results strongly suggest that AICD plays a
role in APP signaling and induces neuronal cell death, which may closely relate to the onset
and progression of AD.
Figure 4. Expression of AICD in P19 cells induced neuronal cell death. After aggregation culture with RA, AICD-ex‐
pressing P19 and control P19 cells carrying vector alone were replated and cultured for the indicated periods on
dishes and allowed to differentiate. Undifferentiated AICD-expressing P19 cells retained epithelial cell-like morpholo‐
gy similar to control cells, while the differentiated cells became round and showed a bipolar morphology with neurite
extension. Two days after replating (Day 2), all cell lines grew well and neurons with long neurites appeared. Four days
after replating (Day 4), control cells still grew well as clusters and many neurons had differentiated from these cells.
However, many AICD-expressing P19 cells showed severe degeneration, becoming spherical with numerous vacuoles
and detached from the culture dishes.
5.2. AICD changes the gene expression profile
If APP signaling exists, AICD should change the expression of certain genes. To examine this
possibility and identify the genes involved in this neuron-specific apoptosis, we performed
DNA microarray analyses to evaluate the changes in the expression of more than 20,000 inde‐
pendent genes induced by AICD through the process of neuron-specific apoptosis [30]. Gene
expression levels were deduced by hybridization signal intensity on the DNA microarrays, and
the data from AICD-overexpressing cells were compared to data from control cells at the same 3
points during culture: 1) the undifferentiated state; 2) after 4 days of aggregation with RA (ag‐
gregated state); and 3) 2 days after replating (differentiated state). According to our expecta‐
tions, AICD was shown to alter the expression of a great many genes; in the presence of AICD,
the expression levels of 277 genes were upregulated by more than 10-fold, while those of 341
genes were downregulated to less than 10% of the original level [30].
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Gene
Symbol
Gene Name Function
Relative Expression Levels (fold)
Undifferentiated Aggregated Differentiated
Non-regulated genes (housekeeping genes)
Actb β-actin cytoskeleton protein -1.2 1.2 1
Sdha
succinate dehydrogenase
subunit A
electron transporter in the TCA cycle and
respiratory chain
-1.1 -1.6 -1.2
Eef1a1
eukaryotic translation
elongation factor-1 alpha 1
essential component for the elongation
phase during protein translation
1 -1.1 1.2
Upregulated genes
Ptprt
protein tyrosine
phosphatase receptor T
protein tyrosine phosphatase that
regulates STAT3 activity
906 204 116
Cpb1 carboxypeptidase B1
hydrolysis of C-terminal end of basic
amino acid peptide bond
16 296 222
Nr2e1 tailless homolog
transcription factor that is essential for
neural stem cell proliferation and self-
renewal
5.8 244 54
Myh1 myosin heavy chain 1
one of the components of the motor
protein myosin
-4.2 259 -1.1
Dnahc7c
axonemal dynein heavy
chain
essential for motility of cilia and flagellae 133 41 43
Alkbh3 alkylation repair homolog 3
AlkB enzyme that repairs methylation
damage in DNA and RNA
69 80 43
Ctgf
connective tissue growth
factor
skeletogenesis/vasculogenesis by
modulating BMP, Wnt, and IGF-I signals
90 54 40
Downregulated genes
Hes5
hairy and enhancer of split
5
transcription factor that inhibits
neurogenesis
-8.7 -3039 -2515
Slc10a6
sodium-dependent organic
anion transporter
transport of sulfoconjugated steroid
hormones and bile acids
-145 -785 -1212
Nid1 nidogen-1 extracellular matrix linker protein -304 -165 -507
LOC213332
analog of Na+-dependent
glucose transporter 1
putative glucose transporter -232 -325 -306
Dtx1 Deltex1 regulator of Notch signaling pathway -30 -85 -691
Rbp4 retinol-binding protein 4
retinol transporter from the liver to
extrahepatic tissues
-525 -100 -24
Col3a1 collagen type III alpha 1 extracellular matrix protein 4.1 -29 -234
Relative expression levels (fold) were estimated from the intensities of hybridization signals. Housekeeping gene ex‐
pression was unaltered in AICD-overexpressing P19 and control P19 cells in all states, suggesting that these genes are
not affected by AICD. These results also indicated that the observed differences in expression were not due to techni‐
cal problems, such as uneven hybridization or poor RNA quality.
Table 2. Expression levels of 7 upregulated and 7 downregulated genes, as well as 3 housekeeping genes
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AICD strongly induced expression of several genes, representative examples of which are
listed in Table 2. For example, AICD-overexpressing P19 cells showed strong expression of
the protein tyrosine phosphatase receptor T (Ptprt) gene at all sampling points: 906-fold,
204-fold, and 116-fold upregulation, in undifferentiated, aggregated, and differentiated
states, respectively, compared with control cells. In contrast to these upregulated genes, the
expression of several genes was strongly inhibited by AICD. Although Hes5 expression was
markedly increased through the process of neural differentiation, with an increase of almost
300-fold in control cells, AICD inhibited this induction. As shown in Fig.5, these results were
confirmed by RT-PCR. Thus, AICD may induce both upregulation and downregulation of
certain genes, suggesting that AICD plays an important role in APP signaling.
Figure 5. RT-PCR analysis of representative 7 upregulated genes and 7 downregulated genes, as well as 3 housekeep‐
ing genes, in P19 cells overexpressing AICD. The RNA samples same as applied to DNA microarray analysis was used in
this RT-PCR analysis.
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We performed Gene Ontology (GO) analysis and classified these upregulated and downre‐
gulated genes according to the GO terms [30]; however, we did not find genes that were sig‐
nificantly related to cell death among those with altered expression. Furthermore, we
evaluated AICD-induced changes in the expression of genes thought to be involved in cell
death in AD [30]; however, we found no significant changes in expression of these genes.
Thus, it is likely that AICD does not directly induce the expression of genes involved in cell
death, but the extreme dynamic changes in gene expression disrupt the homeostasis of cer‐
tain neurons and thus give rise to neuron-specific cell death. Taken together, these results
strongly suggest the existence of APP signaling.
6. Can Aβ clarify all aspects of the onset and progression of AD?
Autosomal dominant mutations in and around the Aβ region of the APP gene, which accel‐
erate proteolytic processing, are responsible for hereditary early-onset AD [3]. The human
APP gene is located on the long arm of chromosome 21 [53], an extra copy of which is
present in individuals with Down’s syndrome (trisomy 21). Patients with Down’s syndrome
develop AD by 40 years of age, most likely due to this gene dosage effect [4]. In addition,
both PS1 and PS2, which are catalytic components of the γ-secretase complex, were identi‐
fied by genetic linkage analyses as the genes responsible for FAD [5-7]. In many cases, fami‐
lial diseases can provide an understanding of the sporadic ones. Therefore, both APP itself
and its proteolytic processing may be responsible for the onset and progression of not only
FAD but also sporadic AD.
As mentioned above, Aβ is the main constituent of amyloid plaque, which is thought to play
a major role in the pathogenesis of AD; its presence is a hallmark of the AD brain. Thus, the
amyloid hypothesis is generally accepted as the mechanism of the onset and progression of
AD. Although an alternative hypothesis has also been proposed, which suggests that solu‐
ble Aβ oligomers rather than insoluble amyloid plaques are responsible for the onset and
progression of AD because the soluble form of the Aβ oligomer is toxic for neurons [100,
101], Aβ still plays a central role in this idea.
However, several doubts have recently been raised regarding the amyloid hypothesis that
Aβ plays a central role in the onset and progression of AD. One of the most critical argu‐
ments against this hypothesis is the presence of high levels of Aβ deposition in many non-
demented elderly people [102], suggesting that Aβ amyloid plaques are not toxic. Indeed,
transgenic mice overproducing Aβ show amyloid deposition mimicking that seen in the AD
brain but do not show neurodegeneration [61]. Furthermore, several anti-Aβ drugs and vac‐
cines have failed to show efficacy in phase III clinical trials [103]. Surprisingly, long-term fol‐
low-up studies showed unexpected problems [104]. Immunization of AD patients with the
anti-Aβ vaccine, AN-1792, cleared Aβ amyloid plaques. Actually, patients with high titers of
antibody against Aβ showed virtually complete plaque removal. However, there was no
evidence of improvement in survival and/or cognitive function, even in patients with high
titers of anti-Aβ antibody [104]. Although several interpretation for this lack of improve‐
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ment have been proposed, these results lead to the idea that both soluble and insoluble
forms of Aβ may not be involved in the onset and progression of AD.
Based on these observations, it has been suggested that AD may be caused by an APP-de‐
rived fragment, just not necessarily Aβ [105]. As both extracellular fragments and AICD are
generated at the same time as Aβ, acceleration of proteolytic processing leads to overpro‐
duction of not only Aβ but also of both the extracellular fragments and AICD. Therefore, it
is likely that the extracellular fragments and/or AICD are responsible for the onset and pro‐
gression of AD. Indeed, AICD has been shown to induce neuron-specific apoptosis, which
leads to AD pathology, as mentioned above.
In addition, it has also been proposed that APP is a ligand of Death receptor 6 (DR6) [106],
which mediates cell death and is expressed at high levels in the human brain regions most
affected by AD. APP is cleaved by β-secretase, releasing the extracellular domain (sAPPβ),
which is further cleaved by an as yet unknown mechanism to release a 35 kDa N-terminal
fragment (N-APP). This N-APP fragment binds DR6 to trigger neurodegeneration through
caspase 6 in axons and caspase 3 in cell bodies [106]. These results suggest that N-APP may
also be involved in the onset and progression of AD.
7. The model of APP signaling
Through this chapter, we discussed the possibility of the existence of APP signaling. It is
likely that disorders of this signaling mechanism are involved in the onset and progression
of AD. As AICD is generated at the same time as Aβ, acceleration of proteolytic processing
leads to overproduction of not only Aβ but also AICD in AD brain as discussed above. Fur‐
thermore, we showed that AICD alters the expression of certain genes and induces neuron-
specific apoptosis [29, 30].
If the APP signaling hypothesis is correct, certain molecules involved in APP signaling may
be attractive candidates for the targets of drug discovery for treating AD. Fig.6 is a schemat‐
ic model of APP signaling. As mentioned above, after cleavage within the JM domain by α-
or β-secretase, AICD is released from the membrane by γ-secretase. Inhibiters for these
proteases are being studied extensively.
As mentioned in section 4.3, non-phosphorylated AICD can bind to the nuclear adaptor pro‐
tein Fe65 [92, 93], which is essential for translocation of AICD to the nucleus. However,
phosphorylated AICD cannot bind to Fe65. These results suggest the possibility that a cer‐
tain stimulus controls APP signaling through phosphorylation and dephosphorylation of
AICD. It has also been shown that the majority of cell membrane-associated APP is phos‐
phorylated specifically at Thr668 in neurons [107]. Therefore, phosphorylated AICD, which is
released from the cell membrane to the cytoplasm by γ-secretase, cannot bind to Fe65 and
thus cannot translocate to the nucleus. Phosphorylated AICD left in the cytosol is rapidly
degraded, probably by the proteasome and/or IDE [88]. However, if AICD is dephosphory‐
lated by certain phosphatase, AICD can binds to Fe65. Thus, AICD/Fe65 complexes may im‐
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mediately translocate to the nucleus, where they mediate expressions of certain target genes
in association with histone acetyltransferase Tip60 [27]. Besides dephosphorylation of AICD,
if phosphorylation of membrane-associated APP is inhibited, non-phosphorylated AICD
may also increase. Therefore, it is likely that non-phosphorylated AICD is involved in the
onset and progression of AD.
Figure 6. Model of APP signaling pathway. The majority of cell membrane-associated APP is phosphorylated within its
ICD in neurons. After cleavage of JM domain by α- or β-secretase, AICD is released from the membrane by γ-secretase.
Phosphorylated AICD cannot bind to the nuclear adaptor protein Fe65, which is thought to be essential for transloca‐
tion of AICD to the nucleus, and thus cannot translocate to the nucleus. Phosphorylated AICD left in the cytosol is rap‐
idly degraded, probably by the proteasome and/or insulin-degrading enzyme (IDE). On the other hand,
dephosphorylated AICD binds to Fe65. Therefore, dephosphorylated AICD/Fe65 complexes immediately translocate
to the nucleus, where they meidate up- and downregulation of certain target genes in association with Tip60.
In addition to these possibilities, it is also likely that AICD is ineffective in the normal brain,
because almost all AICD is degraded rapidly, and APP signaling cannot be transmitted.
However, both AICD and Aβ are overproduced in the AD brain compared to normal brain.
Thus, although the majority of AICD is degraded, a small amount of the remaining AICD
may play a role in signaling and cause neuron-specific cell death in the AD brain. In addi‐
tion, if the degrading activity of AICD is reduced or lost in the AD brain, APP signaling,
which leads to neuron-specific cell death, may be enhanced. Thus, compounds that inhibit
translocation of AICD to the nucleus will be good candidates for AD therapy. From this
point of view, protein phosphatase inhibitors and chemicals that impair the interaction be‐
tween AICD and Fe65 may be potential ones.
8. Conclusion
γ-Secretase was first identified as a protease that cleaves APP within the transmembrane do‐
main and produces Aβ peptides, which are the main hallmark of AD and are thought to be
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involved in the pathogenesis in the AD brains. However, the physiological functions of this
protease remain to be clarified.
The signaling hypothesis for γ-secretase suggesting that its primary function is to regulate
the signaling of type 1 membrane proteins was proposed by analogy of Notch signaling. In
the canonical Notch signaling pathway, ligands bind to the extracellular domain of Notch
expressed on neighboring cells, and trigger sequential proteolytic cleavage. Finally, NICD is
released from the cell membrane by γ-secretase and translocates into the nucleus where it
modulates gene expression through binding to transcription factors. Thus, γ-secretase plays
a central regulatory role in Notch signaling.
While APP is thought to play central roles in the onset and progression of AD, the physio‐
logical functions of this protein also have not yet been fully elucidated. However, it has been
shown that AICD, which is released from the cell membrane by γ-secretase, also translocates
to the nucleus and may function as a transcriptional regulator. These observations suggest
the existence of a signaling mechanism similar to that of Notch.
In this chapter, we focused on the signaling aspects of APP and its pathological roles in AD.
Indeed, we showed that AICD alters gene expression and induces neuron-specific apoptosis.
Thus, it is likely that APP has a signaling mechanism similar to that of Notch and that APP
signaling is at least partially responsible for the onset and progression of AD. If the APP sig‐
naling hypothesis is correct, several molecules involved in APP signaling may be attractive
candidates for the targets of drug discovery for treating AD. Thus, extensive studies about
this issue are expected.
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